Paricalcitol (Zemplar®) capsules for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000407
English
Authors' recommendations:
Paricalcitol (Zemplar®) capsules are not recommended for use within NHS Wales for the treatment of secondary hyperparathyroidism associated with chronic renal insufficiency (chronic kidney disease (CKD) Stages 3 and 4) patients and chronic renal failure (CKD Stage 5) patients on haemodialysis or peritoneal dialysis.
Insufficient evidence of clinical and cost effectiveness was presented for AWMSG to recommend its use within NHS Wales.
Details
Project Status:
Completed
Year Published:
2009
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=131387&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Hyperparathyroidism, Secondary
- Renal Insufficiency, Chronic
- Ergocalciferols
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.